-
公开(公告)号：KR1020130040293A
公开(公告)日：2013-04-24
申请号：KR1020110104949
申请日：2011-10-14
Applicant: 서울대학교산학협력단
IPC: G01N33/574 , C12Q1/68
CPC classification number: G01N33/573 , G01N33/57423 , C12Q1/6886 , G01N33/5302 , G01N33/6857 , G01N33/6893 , G01N2033/57453
Abstract: PURPOSE: A composition for diagnosing lung cancer is provided to early diagnose lung cancer and to ensure sensitivity and specificity. CONSTITUTION: A composition for diagnosing lung cancer contains an antibody which specifically binds to one or more proteins selected from the group consisting of quescin-sulfhydryl oxidase 1, fibrillin-1, isoform A of lamin-A/C, latent-transforming growth factor beta-binding protein 2, galectin-1, Dickkopf-related protein 3, isoform A1-B of heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, stanniocalcin-2, cystatin-C, isoform 1 of connective tissue growth factor, profilin-1, isoform 1 of extracellular matrix protein 1, histone H2B type 2-E, kinesin-like protein KIF26A, zinc finger protein 516, and isoform 1 of A-kinase anchor protein 9. The lung cancer is selected from the group consisting of adenocarcinoma of the lung, squamous cell carcinoma, large cell carcinoma, and small cell cancer. A kit for diagnosing lung cancer contains the composition as an active ingredient. A microarray for diagnosing lung cancer contains the composition as an active ingredient. [Reference numerals] (AA,GG) Patient number; (B1,H1) Gender; (B2,B3,B4,B5,H2,H3,H4) Male; (B6) Female; (CC,II) Age; (D1,J1) Histological classification; (D2,D4,D6,J2,J3,J4) Adenocarcinoma; (D3,D5) Squamous cell carcinoma; (E1,K1) Step; (E2,E5,K4) Step IIA; (E3,E4,E6,K3) Step IB; (F1,L1) Smoking history; (F2,F3) 30 boxes/year; (F4) 15 boxes/year; (F5) 70 boxes/year; (K2) Step IA; (L2) 80 boxes/year; (L3) 40 boxes/year; (MM,NN) Information X;
Abstract translation: 目的：提供诊断肺癌的组合物，以早期诊断肺癌并确保敏感性和特异性。 构成：用于诊断肺癌的组合物含有特异性结合一种或多种选自以下的蛋白质的抗体：蛋白质 - 巯基氧化酶1，原纤维蛋白-1，层状A / C的同种型A，潜伏转化生长因子β 结合蛋白2，半乳凝素-1，Dickkopf相关蛋白3，异源核核糖核蛋白A1异构体A1-B，14-3-3蛋白质ε，猕猴桃素-2，半胱氨酸蛋白酶C，结缔组织生长因子异构体1 -1，细胞外基质蛋白1的同种型1，组蛋白H2B型2-E，驱动蛋白样蛋白KIF26A，锌指蛋白516和A激酶锚蛋白9的同种型1。肺癌选自 肺腺癌，鳞状细胞癌，大细胞癌和小细胞癌。 用于诊断肺癌的试剂盒含有作为活性成分的组合物。 用于诊断肺癌的微阵列包含该组合物作为活性成分。 （附图标记）（AA，GG）患者编号; （B1，H1）性别; （B2，B3，B4，B5，H2，H3，H4）男; （B6）女; （CC，II）年龄; （D1，J1）组织学分类; （D2，D4，D6，J2，J3，J4）腺癌; （D3，D5）鳞状细胞癌; （E1，K1）步骤; （E2，E5，K4）步骤IIA; （E3，E4，E6，K3）步骤1B; （F1，L1）吸烟史; （F2，F3）30箱/年; （F4）15箱/年; （F5）70箱/年; （K2）步骤1A; （L2）80箱/年; （L3）40箱/年; （MM，NN）信息X;
-
12.发明公开
公开(公告)号：KR1020180018052A
公开(公告)日：2018-02-21
申请号：KR1020160102956
申请日：2016-08-12
Applicant: 서울대학교산학협력단
CPC classification number: A61L31/10 , A61L31/12 , A61L31/16 , A61L31/125 , A61L2300/40 , A61L2420/04
Abstract: 본발명은후기내피전구세포의포획및 증식을유도하는의료기구코팅조성물에있어서, 상기코팅조성물은 Nectin-2와반응하는치료에유효한양의일종이상의항체또는이의단편을포함하는것을특징으로하는의료기구코팅조성물및 이를이용한의료기구에대한것이며, 상기코팅조성물을통해혈관의재협착을방지하고, 혈관의재내피화를촉진할수 있다.
Abstract translation: 本发明是用于诱导晚期内皮祖细胞的捕获和增殖的医疗器械包衣组合物，其特征在于所述包衣组合物包含一种或多种有效治疗Nectin-2的抗体或其片段 本发明涉及能够防止血管再狭窄并促进血管再结合的医疗器械用涂敷组合物和使用该组合物的医疗器械。
-
公开(公告)号：KR101535070B1
公开(公告)日：2015-07-10
申请号：KR1020140089522
申请日：2014-07-16
Applicant: 서울대학교산학협력단
CPC classification number: C12N15/85 , C12N5/0607
Abstract: 본발명은 TetO- CMV 프로모터,혈관성장인자유전자염기서열,hEF1a 유전자염기서열,rtTA 유전자염기서열, HA-L 유전자염기서열, HA-R 유전자염기서열을포함하는재조합발현벡터에관한것이다. 본발명에따른재조합발현벡터는바이러스를이용하는기존의형질전환과달리 Talen 시스템을이용하여숙주염색체의 safe harbor 부위에안정적으로혈관성장인자유전자를도입이가능하여안정성문제를개선하였고, 혈관성장인자의발현을임의로조절하고자 Tet-ON 시스템을도입하였으며이로써독시사이클린이처리되었을경우에만혈관성장인자의발현이가능하여효과적인혈관성장인자발현조절이가능하다.
Abstract translation: 本发明涉及重组表达载体，其包含：TetO-CMV启动子; 血管内皮生长因子基因的核苷酸序列; hEF1a基因的核苷酸序列; rtTA基因的核苷酸序列; HA-L基因的核苷酸序列; 和HA-R基因的核苷酸序列。 根据本发明，重组表达载体与使用病毒的常规转化不同，使用Talen系统，使得血管内皮生长因子基因稳定整合到宿主染色体的安全港部分，从而提高稳定性。 此外，引入Tet-ON系统以任意控制血管内皮生长因子的表达，因此当仅治疗多西环素时，血管内皮生长因子的表达是可能的，从而有效地控制血管内皮生长因子的表达。
-
公开(公告)号：KR1020150025697A
公开(公告)日：2015-03-11
申请号：KR1020130103648
申请日：2013-08-30
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/68 , C12Q2600/158 , G01N33/6857 , G01N33/6893
Abstract: The present invention relates to a method for screening formulations used for preventing or treating diseases related to FGF2, which comprises a step of measuring the level of CXCL5 in cells for making bones and vascular endothelial cells processed with FGF2 and candidate materials to prevent or treat diseases related to FGF2 including clone myeloblastic cellular diseases, a screening kit used in the screening method and a formulation obtained by the screening method for treating or preventing diseases related to FGF2. In the present invention, using the screening method is allowed to easily screen the formulation with a high reliability wherein the formulation is used for treating or preventing diseases related to bones caused by excesses FGF2 and other diseases related to hematopoietic stem cells like an effect on movement of hematopoietic stem cell series in bone marrow by the change of bone, thereby being used for manufacturing drugs to treat or prevent diseases related to FGF2 or to hematopoietic stem cell series.
Abstract translation: 本发明涉及筛选用于预防或治疗与FGF2有关的疾病的制剂的方法，该方法包括测量用于制备用FGF2加工的骨骼和血管内皮细胞的细胞中CXCL5的水平和预防或治疗疾病的候选物质的步骤 与FGF2相关，包括克隆成髓细胞疾病，用于筛选方法的筛选试剂盒和通过筛选方法获得的用于治疗或预防与FGF2有关的疾病的制剂。 在本发明中，允许使用筛选方法以高可靠性容易地筛选制剂，其中所述制剂用于治疗或预防与过量的FGF2引起的骨骼相关的疾病和与造血干细胞相关的其它疾病，如对运动的影响 的造血干细胞系列在骨髓中的变化，从而被用于制造药物以治疗或预防与FGF2相关的疾病或造血干细胞系列。
-
公开(公告)号：KR101334123B1
公开(公告)日：2013-11-28
申请号：KR1020110104950
申请日：2011-10-14
Applicant: 서울대학교산학협력단
IPC: G01N33/574 , G01N33/68 , C12Q1/68
Abstract: 본 발명은 소세포폐암의 조기 진단에 유용한 바이오마커로서 퀴혈청 파라옥소나제 1(Serum paraoxonase 1), 피브릴린-1(Fibrillin-1), 리포폴리사카라이드-반응 및 베이지-유사 앵커 단백질(Isoform 1 of Lipopolysaccharide-responsive and beige-like anchor protein), 아포리포단백질 D(Apolipoprotein D), 세로트랜스페린(Serotransferrin), 칼리스타틴(Kallistatin), 혈장 칼리클레인(Plasma kallikrein), 루미칸(Lumican), 히스티딘-리치 당단백질(Histidine-rich glycoprotein), 알파-2-HS-당단백질(Alpha-2-HS-glycoprotein), 알파-1B-당단백질(Alpha-1B-glycoprotein) 및 아포리포단백질A-IV(Apolipoprotein A-IV)로 이루어진 군에서 선택된 하나 이상의 단백질 또는 합토글로빈(Haptoglobin), 헤모펙신(Hemopexin), C4b-결합 단백질 알파 체인(C4b-binding protein alpha chain), 보체성분 C9(Complement component C9), CD5 유사 항원(CD5 antigen-like), 인터-알파-트립신 억� ��제 중쇄 H2(Inter-alpha-trypsin inhibitor heavy chain H2), 혈청 아밀로이드 P 성분(Serum amyloid P component), 인터-알파-트립신 억제제 중쇄 H4(Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4), 합토글로빈 관련 단백질(Isoform 1 of Haptoglobin-related protein), 알파-1-안티키모트립신(ALPHA-1-antichymotrypsin) 및 알파-1-안티트립신(Isoform 1 of Alpha-1-antitrypsin)으로 이루어진 군에서 선택된 하나 이상의 단백질을 제공한다.
-
Patent Agency Ranking
公开(公告)号：KR101989465B1
公开(公告)日：2019-06-14
申请号：KR1020170111049
申请日：2017-08-31
Applicant: 서울대학교산학협력단
IPC: C12Q1/68
-
公开(公告)号：KR101850779B1
公开(公告)日：2018-04-20
申请号：KR1020160102957
申请日：2016-08-12
Applicant: 서울대학교산학협력단
Abstract: 본발명은후기내피전구세포의포획및 증식을유도하는의료기구코팅조성물에있어서, 상기코팅조성물은 HIP와반응하는치료에유효한양의일종이상의항체또는이의단편을포함하는것을특징으로하는의료기구코팅조성물및 이를이용한의료기구에대한것이며, 상기코팅조성물을통해혈관의재협착을방지하고, 혈관의재내피화를촉진할수 있다.
-
公开(公告)号：KR101465596B1
公开(公告)日：2014-11-27
申请号：KR1020140089521
申请日：2014-07-16
Applicant: 서울대학교산학협력단
CPC classification number: A61K9/06 , A61K38/1833 , A61K38/1866 , A61K2121/00
Abstract: 본 발명은 후기내피전구세포를 RGD-알지네이트 용액에 혼합하여 현탁액을 제조하는 단계; 혈관내피성장인자(VEGF)와 간세포성장인자(HGF)를 상기 현탁액에 추가하는 단계; 상기 현탁액을 전기분무시키는 단계를 포함하는 것을 특징으로 하는 허혈성 질환 치료용 주입식 마이크로젤의 제조방법이다.상기 주입식 마이크로젤은 후기내포전구세포등 혈관치료세포의 생존률을 높이고 마이크로젤 안에 함유된 혈관내피성장인자(VEGF)및 간세포성장인자(HGF)등의 혈관성장인자들을 지속적으로 방출하여 더욱 향상된 신혈관 생성효과를 발휘할 수 있다.
Abstract translation: 本发明涉及一种制备可注射微凝胶以治疗缺血性疾病的方法，其包括以下步骤：通过将晚期内皮祖细胞与RGD-藻酸盐溶液混合来制备悬浮液; 将血管内皮生长因子（VEGF）和肝细胞生长因子（HGF）加入到悬浮液中; 并电喷雾悬浮液。 可注射的微凝胶增加血管治疗细胞如晚期内皮祖细胞的存活，并连续释放微凝胶中所含的血管生长因子如VEGF和HGF; 从而发挥更大的血管生成作用。
-
公开(公告)号：KR1020140089243A
公开(公告)日：2014-07-14
申请号：KR1020130001267
申请日：2013-01-04
Applicant: 서울대학교산학협력단
IPC: A61K39/395 , G01N33/563 , G01N33/68 , G01N33/574
CPC classification number: C12N9/20 , G01N33/57423
Abstract: The present invention relates to a biomarker which is useful for the early diagnosis of lung cancer. The biomarker is a lung cancer-diagnosing composition including an antibody which is specific to a GPI specific phospholipase D1 (GPLD1) protein and a lung cancer-diagnosing composition including a primer or a probe which is specific to nucleic acid encoding the protein. The biomarker of the present invention can be usefully used for early lung cancer diagnosis and also to evaluate the progress of diseases and give a prognosis before and after treatment.
Abstract translation: 本发明涉及可用于肺癌早期诊断的生物标志物。 该生物标志物是包含对GPI特异性磷脂酶D1（GPLD1）蛋白特异的抗体的肺癌诊断用组合物，以及包含编码该蛋白质的核酸特异性的引物或探针的肺癌诊断用组合物。 本发明的生物标志物可以有效地用于早期肺癌诊断，并且还可以评估疾病的进展并在治疗前后给出预后。
-
公开(公告)号：KR101297309B1
公开(公告)日：2013-08-16
申请号：KR1020110104949
申请日：2011-10-14
Applicant: 서울대학교산학협력단
IPC: G01N33/574 , C12Q1/68
CPC classification number: G01N33/573 , G01N33/57423
Abstract: 본 발명은 폐암의 조기 진단에 유용한 바이오마커로서 퀴에신-설프히드릴 옥시다제 1(Quescin-sulfhydryl oxidase 1), 피브릴린-1(Fibrillin-1), 라민-A/C(Isoform A of Lamin-A/C), 잠재 형질전환증식인자 베타-결합단백질 2(Latent-transforming growth factor beta-binding protein 2), 갈렉틴-1(Galectin-1), 딕오프관련단백질 3(highly similar to Dickkopf-related protein 3), 이질성 핵 리보핵단백질 A1(Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1), 14-3-3 엡실론 단백질(14-3-3 protein epsilon), 시스타틴-C(Cystatin-C), 결합 조직 성장인자 1(Isoform 1 of Connective tissue growth factor), 프로필린-1(Profilin-1), 세포외 간질단백질 1(Isoform 1 of Extracellular matrix protein 1), 히스톤 H2B 타입 2-E(Histone H2B type 2-E), 키네신 유사 단백질 KIF26A(Kinesin-like protein KIF26A), 징크 핑거 단백질 516(Zinc finger protein 516) 및 A-키나제 앵커 단백질 9(Isoform 1 of A-kinase anchor protein 9)로 이루어진 군에서 선택된 하나 이상의 단백질을 제공한다.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.026 seconds)
